首页> 美国卫生研究院文献>Translational Lung Cancer Research >Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials

【2h】

Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials

机译：总体存活率仍是维持性非小细胞肺癌研究的主要终点吗？ III期随机试验分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundIn advanced non-small cell lung cancer (NSCLC), the increasing number of active compounds available in second line settings makes overall survival (OS) with maintenance treatment a not frequently observed endpoint. A literature review was conducted to examine whether post-progression survival (PPS) correlates with OS in maintenance trials.

机译：背景技术在晚期非小细胞肺癌（NSCLC）中，在二线治疗中可用的活性化合物数量增加，使得维持治疗的总生存期（OS）不再是经常观察到的终点。进行了文献综述，以检查维持试验中进展后生存率（PPS）是否与OS相关。

著录项

期刊名称 Translational Lung Cancer Research
作者
Fausto Petrelli; Sandro Barni;
展开▼
作者单位

展开▼
年(卷),期 2013(2),1
年度 2013
页码 6–13
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. [J] . Koch A, Bergman B, Holmberg E, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第10期

机译：塞来昔布对晚期非小细胞肺癌患者生存的影响：瑞典肺癌研究小组进行的一项双盲随机临床III期临床试验（CYCLUS研究）。
2. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer [J] . Novello Silvia, Kaiser Rolf, Mellemgaard Anders, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第3期

机译：分析烟雾肺1试验的患者报告的结果：一种随机，双盲，安慰剂控制，第三阶段九丁酰胺患者在高小细胞肺癌患者中的研究III研究
3. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) [J] . OBrien Mary E. R., Gaafar Rabab, Hasan Baktiar, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第12期

机译：一线化疗后非进展性非小细胞肺癌患者的维持帕唑帕尼与安慰剂比较：肺癌组的双盲随机III期研究，EORTC 08092（EudraCT：2010-018566-23，NCT01208064）
4. Gene expression profiles predict survival of patients with advanced non-small cell lung cancers [C] . Harun Roslan, Hadi Jalal, Mhazir Nur Shukriyah, 2011 Fourth International Conference on Modeling, Simulation and Applied Optimization . 2011

机译：基因表达谱预测晚期非小细胞肺癌患者的生存
5. The role of NAD(P)H:quinone oxidoreductase 1 in non-small cell lung cancer tumorigenesis and lung cancer stem cell maintenance [D] . Madajewski, Brian. 2016

机译：NAD（P）H：醌氧化还原酶1在非小细胞肺癌的发生和肺癌干细胞维持中的作用
6. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial [O] . Anil Tibdewal, Jai Prakash Agarwal, Shashank Srinivasan, 2021

机译：标准维持治疗与局部合并放射治疗和标准维持治疗在1-5位寡核差距非小细胞肺癌中：III期随机对照试验的研究方案
7. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial [O] . Anil Tibdewal, Jai Prakash Agarwal, Shashank Srinivasan, 2021

机译：标准维持治疗与局部合并放射治疗和标准维持治疗在1-5位寡核差距非小细胞肺癌中：III期随机对照试验的研究方案

Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials

摘要

著录项

相似文献

相关主题

期刊订阅